Vaccine News and Research

Latest Vaccine News and Research

SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026

The Southwest National Primate Research Center at Texas Biomedical Research Institute has been awarded more than $37 million from the National Institutes of Health to continue operations into 2026.

15 Jun 2021

Adapting COVID-19 vaccination strategies based on SARS-CoV-2’s evolution

Given the risk of SARS-CoV-2 developing new variants in unvaccinated individuals, vaccination sites are crucial. However, new research from the University of Michigan, USA, shows current vaccination programs may be worsening regional outbreaks when viral strains and SARS-CoV-2 escape mutations outdo vaccination rates.

15 Jun 2021

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

A new study, released as a preprint on the bioRxiv* server, describes the biological effects induced by mutations in two circulating VOCs. These are the alpha and beta strains, also called B.1.1.7 and B.1.351, respectively.

15 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Being vaccinated doesn’t mean you must go maskless. Here’s why.

For more than a year, public health officials have repeatedly told us that masks save lives. They've warned us to keep our distance from our neighbors, who've morphed into disease vectors before our eyes.

15 Jun 2021

CDC reports rare cases of heart inflammation in young men after mRNA COVID-19 vaccination

Vaccination efforts have rolled out in most countries starting in the last quarter of 2020 with more than 2.37 billion vaccines administered worldwide so far. However, reports of cardiac inflammation (myocarditis and pericarditis) occurring after the mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna) have increased in the United States since April 2021.

15 Jun 2021

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers in Canada have shown that the long-lasting immunity that develops following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by different T cell responses than those observed for influenza A virus-specific immune memory.

14 Jun 2021

SARS-CoV-2 variant of concern could cause further epidemics in UK

The team – from the University of Warwick, the University of Manchester, and the University of Oxford – say that a variant of concern that has either a substantial transmission advantage over resident lineages, or the ability to evade vaccine- or infection-induced immunity, can be expected to drive a wave of infections and hospitalizations similar to that seen in the country during the winter of 2020-21.

14 Jun 2021

South African and Brazilian SARS-CoV-2 variants overtake UK variant in French regions

Researchers have found that the variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that were initially identified in South Africa (B.1.351) and Brazil (P.1) appear to be spreading more quickly in some areas of France than the previously dominant UK variant B.1.1.7.

14 Jun 2021

Researchers examine the importance of time after COVID-19 vaccination

A new study has been published on the medRxiv* preprint server, which deals with the importance of time post-vaccination based on the quantification of VOC immune evasion. The current study developed a toy model to estimate the effectiveness of the vaccines against VOC over time. Researchers have shown that the estimated value is highly dependent on time post-vaccination. Additionally, this model can describe the implications of changes in vaccine efficacy against VOC.

14 Jun 2021

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.

14 Jun 2021

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

The Native Antigen Company, part of LGC Clinical Diagnostics, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards.

From The Native Antigen Company 14 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

A new commentary, published as an ‘In-Press Preview’ in the Journal of Clinical Investigation, addresses the salient issue of vaccination against the coronavirus disease (COVID-19) in pregnancy and potential antibody transfer to the fetus – and provides the evidence in support of messenger RNA (mRNA) vaccine safety and efficacy for both maternal and child health.

13 Jun 2021

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.

13 Jun 2021

FDA takes steps to allow critically needed supply of Janssen COVID-19 vaccine

Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available.

11 Jun 2021

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

In British Columbia (BC), Canada, vaccination against coronavirus disease 2019 (COVID-19) began with the Pfizer/Moderna mRNA (messenger ribonucleic acid) vaccines began with nursing home residents and frontline healthcare workers. These are known to have a high protective efficacy of 92-93% after a single dose, but this data comes from younger and healthy adults, for the most part.

11 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Has COVID-19 vaccine confidence dropped following the pause of Johnson & Johnson/Janssen?

A new study, which was conducted by Vishala Mishra and Joseph P. Dexter at Madras Medical College, Chennai, India, suggests that the infamous pause in the administration of the Johnson & Johnson (J&J)/Janssen COVID-19 vaccine, advised by the FDA, has left doubt about the veracity of vaccine safety claims. This is a development that may have engendered vaccine hesitancy in a segment of the population.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

Vaccine News and Research

Latest Vaccine News and Research

SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026

Adapting COVID-19 vaccination strategies based on SARS-CoV-2’s evolution

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

Being vaccinated doesn’t mean you must go maskless. Here’s why.

CDC reports rare cases of heart inflammation in young men after mRNA COVID-19 vaccination

Immune memory responses differ between SARS-CoV-2 and influenza A

SARS-CoV-2 variant of concern could cause further epidemics in UK

South African and Brazilian SARS-CoV-2 variants overtake UK variant in French regions

Researchers examine the importance of time after COVID-19 vaccination

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

FDA takes steps to allow critically needed supply of Janssen COVID-19 vaccine

High single-dose efficacy of Pfizer vaccine against SARS-CoV-2 in older adults

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Has COVID-19 vaccine confidence dropped following the pause of Johnson & Johnson/Janssen?

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in